Product details
Target: CD22
Targeting Cell Type: T cell
Targeting Diseases: Acute lymphoblastic leukemia (ALL)
Generation: Second, Third
Vector Name: pCDH
Vector Type: Lentiviral vector
Receptor Construction: scFv-CD28-CD3ζ, scFv-41BB-CD3ζ, scFv-CD4-FcεRIγ, scFv-CD28-41BB-CD3ζ, scFv-CD28-OX40-CD3ζ......
Targeting Cell Type: T cell
Targeting Diseases: Acute lymphoblastic leukemia (ALL)
Generation: Second, Third
Vector Name: pCDH
Vector Type: Lentiviral vector
Receptor Construction: scFv-CD28-CD3ζ, scFv-41BB-CD3ζ, scFv-CD4-FcεRIγ, scFv-CD28-41BB-CD3ζ, scFv-CD28-OX40-CD3ζ......
Target | Clone | Host | Target Species | Gene Name | Gene ID | Synonyms |
CD22 | IS7 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 5.8HK | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 726830 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 7 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 5K249 | Rat | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 5F25 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 5B18 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 4C3 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 3H4 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 3H1112 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 340 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 308501 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 2H1C4 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 26 | Rabbit | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 13 | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 060 | Rabbit | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | 026 | Rabbit | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | Pinatuzumab | Humanized | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | Bectumomab | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | Moxetumomab | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |
CD22 | Inotuzumab | Mouse | Human | CD22 Molecule | 933 | B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2 |